Ovid Therapeutics is followed by a relatively small but bullish group of sell-side analysts. Reviewing individual targets that can be attributed to a named firm and analyst, 11 targets were collected, spanning roughly $4.00 to $9.00. The arithmetic mean of these figures is about $6.05, which rounds to a clean central target of $6.00.
The range is unusually wide, which is normal for a pre-revenue biotech whose value depends on clinical results. At the conservative end, LifeSci Capital carries a $4.00 target, while H.C. Wainwright (Raghuram Selvaraju) holds a $5.00 target and B. Riley sits at $5.00. In the middle, Cantor Fitzgerald (Imogen Mansfield) initiated at $6.00, and Wedbush (Laura Chico) and Guggenheim (Delma Caiati) both use $7.00. Roth Capital (Boobalan Pachaiyappan) is at $8.00, and Oppenheimer holds the high at $9.00.
Recent actions have leaned bullish: Wedbush, Roth Capital, and H.C. Wainwright have all raised targets during 2026, while Wolfe Research, Cantor Fitzgerald, and Guggenheim initiated coverage with Buy or Outperform ratings. The divergence reflects differing assumptions about how much value to assign to OV4071, Ovid's most speculative but potentially transformative asset.
OVID trades near $2.80, with a market capitalization around $530 million and a 52-week range of $1.18 to $3.105. Reaching $6.00 requires a move of roughly 114%, which is very large by any standard and implies more than a doubling of the share price.
That path is not built on current earnings or revenue. Ovid reported a third-quarter 2026 net loss of about $20.8 million, or $0.10 per share, on essentially minimal product revenue. The company held roughly $161.4 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which management expects to fund key studies well into the future. A move toward the target would depend almost entirely on successful clinical data, not near-term financial results.
The bull case rests on two programs. OV329 is a next-generation GABA-AT inhibitor for drug-resistant epilepsy designed to retain the efficacy of vigabatrin while avoiding its hallmark eye toxicity. Phase 1 data showed a favorable safety profile with no ocular findings, and the company is enrolling a photosensitivity proof-of-concept study plus a Phase 2 focal epilepsy trial. OV4071 is an oral, first-in-class direct activator of KCC2, a target the industry has pursued for two decades; Ovid is positioning it across schizophrenia, psychosis, and other neuropsychiatric conditions.
Analysts such as Wedbush have argued that success in Parkinson's disease psychosis alone could add several dollars per share to valuation. Positive readouts in 2027, a de-risked safety profile, and a cash runway extending toward 2029 all support the bullish targets.
The principal obstacle is binary clinical risk. If the OV329 Phase 2 trial or the OV4071 translational study disappoints, the pipeline's value could compress sharply, and most price targets would likely be cut. Ovid also generates minimal revenue, so it depends on its cash balance and, potentially, future equity raises; a $250 million mixed securities shelf was recently filed, highlighting dilution risk. The stock has no meaningful earnings support, and its valuation is driven by sentiment around data readouts that remain months away.
OVID has traded between roughly $1.18 and $3.10 over the past 52 weeks, after rising more than 100% over the prior year. The $3.00 to $3.10 area marks a prior high and near-term resistance zone, while the $2.60 to $2.65 region has acted as short-term support. A sustained move above the 52-week high near $3.10 would be a notable technical development, but the $6.00 target sits far above any established price level, underscoring how much depends on fundamentals rather than chart structure.
Analyst price targets typically reflect a roughly 12-month research horizon, though the relevant horizon here extends into 2027 given the clinical calendar. Key items to monitor include the OV329 photosensitivity proof-of-concept readout expected in the first quarter of 2027, the OV4071 translational biomarker readout also targeted for early 2027, the start of a tuberous sclerosis complex study, and OV329 Phase 2 data anticipated in the second half of 2027. Analyst revisions around these events, plus quarterly cash balances and any financing activity, will be the most important signals.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like Ovid, traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual review allows. Explore the signals to add an automated layer to your market research.
The $6.00 central target is the average of 11 analyst price targets spanning $4.00 to $9.00, implying a roughly 114% move from the current price near $2.80. The wide range reflects genuine disagreement about Ovid's pipeline, particularly the speculative OV4071 program. Support rests on differentiated drug mechanisms, a de-risked safety profile, and a cash runway extending into 2029, while the chief risks are binary clinical outcomes, minimal revenue, and potential dilution. Whether OVID reaches $6.00 will depend on data readouts across 2027 rather than near-term financials, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, OVID has been loosely correlated with CLDX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then CLDX could also see price increases.
| Ticker / NAME | Correlation To OVID | 1D Price Change % | ||
|---|---|---|---|---|
| OVID | 100% | -1.75% | ||
| CLDX - OVID | 42% Loosely correlated | -1.89% | ||
| SLDB - OVID | 42% Loosely correlated | +2.14% | ||
| SANA - OVID | 40% Loosely correlated | -1.42% | ||
| VIR - OVID | 40% Loosely correlated | -3.63% | ||
| CADL - OVID | 40% Loosely correlated | -1.48% | ||
More | ||||